Price Target Update: Bullish Sentiment Abounds
A wave of optimism has buoyed Glaukos (NYSE:GKOS) as the average one-year price target for the stock has been pumped up to 104.69 per share. This marks a substantial 13.83% surge from the previous estimate reported just a few months back on January 16, 2024. Market analysts have fine-tuned their projections, with the most recent targets ranging from a sturdy 84.84 at the floor to a towering 120.75 at the peak per share. The revised average price target translates to a remarkable 16.88% boost from the latest closing price of 89.57 per share.
Fundamentally Speaking: Riding the Investor Surge
What is the Fund Sentiment?
Over 570 funds or institutions have joined the Glaukos party, nurturing a growing sense of confidence with an increase of 34 additional owners or 6.31% in the past quarter. The average portfolio weight dedicated to GKOS across all funds stands at 0.25%, marking a moderate 3.53% dip. Institutional holdings have seen a notable uptick over the last three months, with shares owned escalating by 1.57% to 62,531K shares. The put/call ratio of GKOS sits at 2.19, painting a slightly bearish picture in the eyes of investors, who remain cautiously optimistic.
What are Other Shareholders Doing?
IJR – iShares Core S&P Small-Cap ETF is on board with 3,285K shares, reflecting a solid 6.74% ownership of the company. Notably, the fund scaled back its stake slightly from the prior filing, showing a dip of 2.81%. However, overall, the firm increased its portfolio allocation in GKOS by a commendable 6.63% over the last quarter.
Brown Capital Management has been bolstering its position in Glaukos, holding 2,698K shares that represent a significant 5.53% ownership of the company. The firm reported a noteworthy increase of 3.31% in its holdings compared to the previous filing, exemplifying a 6.95% surge in its portfolio allocation in GKOS over the quarter.
Contrary to the trend, Fred Alger Management trimmed its position in Glaukos, now holding 1,645K shares amounting to 3.37% ownership of the company. The firm reported a substantial 8.24% decrease in its stake, with a 9.71% reduction in its portfolio allocation in GKOS over the past quarter.
Meanwhile, Janus Henderson Group has also made some adjustments, now holding 1,617K shares or 3.31% ownership of the company. The firm, which demonstrated a minor increase of 0.08% in its stake, curbed its portfolio allocation in GKOS by a significant 68.48% over the last quarter, showcasing varying sentiments among shareholders.
Invesco took a different stance, strengthening its position with 1,573K shares representing 3.22% ownership of Glaukos. The firm reported a notable 7.79% increase in its shares, while paradoxically slashing its portfolio allocation in GKOS by a notable 90.78% during the quarter.
Delving into Glaukos
Glaukos (www.glaukos.com) has been making waves in the world of ophthalmic medical technology and pharmaceuticals with a keen focus on innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company’s pioneering work in Micro-Invasive Glaucoma Surgery (MIGS) has upended traditional treatment and management approaches in glaucoma. From the groundbreaking iStent to the latest iStent inject W device launched in 2020, Glaukos continues to push boundaries. In the realm of corneal health, the company’s suite of single-use pharmaceuticals aims to fortify, stabilize, and reshape the cornea through corneal collagen cross-linking, addressing a range of disorders and refractive conditions. Leveraging its platform technology, Glaukos is on a mission to build a proprietary portfolio of micro-scale surgical and pharmaceutical interventions across glaucoma, corneal health, and retinal diseases.
Fintel stands as a beacon of investing research prowess for individual investors, traders, financial advisors, and small hedge funds, offering a comprehensive analysis of market dynamics and trends, enabling informed decision-making.
Curious to dive deeper into the world of investing? Click to Learn More or source the original content on Fintel.
The insightful views and opinions expounded in this narrative are the author’s own and do not necessarily mirror those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
